ClinicalTrials.gg
RecruitingNCT07594132Updated Oct 22, 2026

Randomized Trial of Next Generation Fluoroscopy System vs. Conventional Fluoroscopy System in Endoscopy

An interventional study of Fluoroscopy-guided endoscopic procedure in Radiation Exposure, sponsored by Orlando Health, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Orlando Health, Inc. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 22, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Fluoroscopy is an integral part of both basic and advanced gastrointestinal endoscopy procedures. Given the risks of radiation exposure and inherent limitations of preventive measures, there is a need for additional effective protective methods.

In this randomized trial, we will be comparing radiation exposure between a next generation fluoroscopy system and conventional fluoroscopy system during fluoroscopy-guided endoscopic procedures.

Read the detailed description

Fluoroscopy is an integral part of both basic and advanced gastrointestinal endoscopy procedures such as stricture dilation, enteral feeding tube placement, double balloon enteroscopy, endoscopic retrograde cholangiopancreatography (ERCP) and interventional endoscopic ultrasound (EUS). Use of fluoroscopy exposes patients, gastroenterologists and endoscopy support personnel to ionizing radiation. While exposure to high-dose-rate ionizing radiation has been shown to be associated with genomic instability, data indicate that exposure to even low-dose radiation, typically utilized for diagnostic imaging, may be associated with an increase in cancer mortality. The lifetime cancer risk is based on the effective dose (ED) of radiation received, which is measured in sieverts (Sv).

In a recent study conducted at a high-volume endoscopy center, the estimated dose equivalent at eye level was estimated to be 126 mSv for an endoscopist performing 500 therapeutic ERCPs per year. Consequently, exposure to ionizing radiation is considered a health hazard to patients as well as gastroenterologists and endoscopy support personnel. As such, appropriate measures to keep radiation exposure as low as reasonably achievable (ALARA) should be implemented. Professional societies such as the American Society for Gastrointestinal Endoscopy (ASGE) and the European Society of Gastrointestinal Endoscopy (ESGE) have published guidelines on radiation safety.

The two main sources of radiation during fluoroscopic procedures are the incident beam, which is the main source of radiation to the patient, and scatter radiation that emanates from the patient's body, which is the main source of radiation to individuals around the patient. Larger the radiation dose to the patient, the greater the scatter. Attempts to minimize radiation exposure include decreasing fluoroscopy time, using pulsed fluoroscopy, increasing the distance from radiation source, shielding, limiting magnification, using collimation, altering x-ray beam angulation, use of artificial intelligence fluoroscopy system, and avoiding use of C-arm units or over-couch x-ray systems. Use of personal protective equipment also reduces occupational exposure; however, many gastroenterologists performing ERCP do not routinely wear optimal protective clothing.

Given the risks of radiation exposure and inherent limitations of the preventive measures outlined, there is a need for additional effective protective methods that are easy to implement. The Soteria E-View system is an FDA-approved, next generation fluoroscopy system that is new to Orlando Health, for use in fluoroscopy-guided endoscopic procedures per standard of care (Omega Medical Imaging, Orlando Florida, USA). The system has been designed to minimize radiation exposure to patients and medical personnel by integrating second-generation artificial intelligence framework (for improved system performance and responsiveness), upgraded C-arm and tables (with enhanced lead flaps along the edges of the table), fluoroless positioning (to reduce reliance on fluoroscopy for positioning steps), reducing frame rate, and robotic system design (to enable automated positioning and movement).

The objective of the study is to compare the radiation exposure and scatter effect between the next generatoin fluoroscopy system and conventional fluoroscopy system during fluoroscopy-guided endoscopic procedures.

02

Conditions studied

  • Radiation Exposure

Keywords

  • Endoscopic ultrasound
  • Endoscopic retrograde cholangiopancreatography
  • Endoscopy
  • Fluoroscopy
03

In context

Lead sponsor

Orlando Health, Inc. is the lead sponsor of 28 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Patients undergoing fluoroscopy-guided endoscopic procedure
  • Physicians and anesthesia staff participating in endoscopic procedures

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Active comparator
    Next generation fluoroscopy system

    Patients will undergo fluroscopy-guided endoscopic procedure using the next generation fluoroscopy system (Soteria, Omega Medical Imaging).

    Procedure: Fluoroscopy-guided endoscopic procedure

  • Active comparator
    Conventional fluoroscopy system

    Patients will undergo fluroscopy-guided endoscopic procedure using conventional fluoroscopy system (OEC Elite, GE Healthcare).

    Procedure: Fluoroscopy-guided endoscopic procedure

Interventions

  • ProcedureFluoroscopy-guided endoscopic procedure

    Patients will be undergoing fluoroscopy-guided endoscopic procedure

06

What researchers measure

Primary outcomes

  1. Radiation scatter

    Compare the level of radiation scatter during fluoroscopy-guided endoscopic procedures between the next generation fluoroscopy system and conventional fluoroscopy system.

    Time frame: 1 day

Secondary outcomes

  1. Radiation exposure

    Compare the level of radiation exposure in patients undergoing fluoroscopy-guided endoscopic procedures between the next generation fluoroscopy system and conventional fluoroscopy system.

    Time frame: 1 day

  2. Total procedure duration

    Total duration of fluoroscopy-guided endoscopic procedure

    Time frame: 1 day

  3. Duration of fluoroscopy

    Total duration of fluoroscopy usage during the endoscopic procedure

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Jun 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 18, 2026
StartActual
Jun 25, 2026was May 2026
Primary completionEst.
Dec 2027
CompletionEst.
Apr 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 2026→Jun 25, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date May 2026→Jun 25, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07594132
Lead sponsor
Orlando Health, Inc.
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Jun 25, 2026
Primary completion
Dec 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Ji Young Bang
Contact
jiyoung.bang@orlandohealth.com
321-842-2273
Barbara J Broome
Contact
Barbara.Broome@orlandohealth.com
321-841-3742
Ji Young Bang
principal investigator · Orlando Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion